Kainos Medicine Inc (220250)

Currency in KRW
20,200
0(0.00%)
Closed·
Showing Kainos Medicine historical data. For real-time data please try another search
Day's Range
19,80020,200
52 wk Range
020,200
Key Statistics
Bid/Ask
20,000.00 / 20,200.00
Prev. Close
20,000
Open
20,100
Day's Range
19,800-20,200
52 wk Range
0-0
Volume
-
Average Volume (3m)
48.54K
1-Year Change
0%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Kainos Medicine Inc Company Profile

Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company’s product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-cancer agent to treat acute myeloid leukemia, as well as small molecule immuno-oncology drugs that modulate anti-cancer abilities of immune cells. In addition, the company is involved in the discovery of a Hepatitis B drug. It has a collaboration agreement with Emmaus Life Sciences, Inc. for the preclinical development of IRAK4 inhibitor as potential anti-cancer drug. The company was founded in 2007 and is headquartered in Seongnam-si, South Korea.

Earnings

Latest Release
Apr 30, 2020
EPS / Forecast
4.14 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

220250 Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.